Abstract:Huntington’s Disease (HD) is a neurodegenerative disorder, part of the nine identified inherited polyglutamine (polyQ) diseases. Most commonly, HD pathophysiology manifests in middle-aged adults with symptoms including progressive loss of motor control, cognitive decline, and psychiatric disturbances. Associated with the pathophysiology of HD is the formation of insoluble fragments of the huntingtin protein (htt) that tend to aggregate in the nucleus and cytoplasm of neurons. To track both the intracellular progression of the aggregation phenotype as well as the physiological deficits associated with mutant htt, two constructs of human HTT were expressed with varying polyQ lengths, non-pathogenic-htt (Q15, NP-htt) and pathogenic-htt (Q138, P-htt), with an N-terminal RFP tag for visualization. P-htt aggregates accumulate in the ventral nerve cord cell bodies as early as 24 hours post hatching and significant aggregates form in the segmental nerve branches at 48 hours post hatching. Organelle trafficking up-and downstream of aggregates formed in motor neurons showed severe deficits in trafficking dynamics. To explore putative downstream deficits of htt aggregation, ultrastructural changes of presynaptic motor neurons and muscles were assessed, but no significant effects were observed. However, the force and kinetics of muscle contractions were severely affected in P-htt animals, reminiscent of human chorea. Reduced muscle force production translated to altered locomotory behavior. A novel HD aggregation model was established to track htt aggregation throughout adulthood in the wing, showing similar aggregation patterns with larvae. Expressing P-htt in the adult nervous system resulted in significantly reduced lifespan, which could be partially rescued by feeding flies the mTOR inhibitor rapamycin. These findings advance our understanding of htt aggregate progression as well the downstream physiological impacts on the nervous system and peripheral tissues.

Huntingtin-associated Protein-1 is a Modifier of the Age-at-onset of Huntington's Disease.

HAP40 is a conserved central regulator of Huntingtin and a specific modulator of mutant Huntingtin toxicity

A Huntingtin-Associated Protein Enriched in Brain with Implications for Pathology

A modifier of Huntington's disease onset at the MLH1 locus

A Human Hap1 Homologue - Cloning, Expression, and Interaction with Huntingtin

HAP40 is a conserved central regulator of Huntingtin and a potential modulator of Huntington's disease pathogenesis

HAP40 modulates mutant Huntingtin aggregation and toxicity in Huntington's disease mice

Huntingtin Interacting Proteins and Pathological Implications

HAP40 Modulates Mutant Huntingtin Aggregation and Toxicity in Huntington’s Disease Mice

Impaired Α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Trafficking and Function by Mutant Huntingtin

N-Terminal Mutant Huntingtin Associates with Mitochondria and Impairs Mitochondrial Trafficking

Mutant Huntingtin in Glial Cells Exacerbates Neurological Symptoms of Huntington Disease Mice

Pathological Polyq Expansion Does Not Alter the Conformation of the Huntingtin-HAP40 Complex.

Ccg Polymorphisms in the Huntingtin Gene Have No Effect on the Pathogenesis of Patients with Huntington'S Disease in Mainland Chinese Families

Soluble N-terminal Fragment of Mutant Huntingtin Protein Impairs Mitochondrial Axonal Transport in Cultured Hippocampal Neurons.

Synaptic Mutant Huntingtin Inhibits Synapsin-1 Phosphorylation And Causes Neurological Symptoms

A PIAS1 Protective Variant S510G Delays polyQ Disease Onset by Modifying Protein Homeostasis

Huntingtin Forms Toxic Nh2-Terminal Fragment Complexes That Are Promoted By The Age-Dependent Decrease In Proteasome Activity

Regulation of intracellular HAP1 trafficking.

Developmental and physiological impacts of pathogenic human huntingtin protein in the nervous system

Accumulation of N-terminal Mutant Huntingtin in Mouse and Monkey Models Implicated As a Pathogenic Mechanism in Huntington's Disease